Vycor Announces Addition to Board of Directors
03 May 2013 - 10:30PM
Marketwired
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO) announced today that it
is adding to the expertise on its board of directors with the
appointment of Lowell Rush as independent director and Chairman of
a newly-formed Audit Committee. At the same time Heather Vinas, who
has remained on the Board since stepping down as President in May
2010, will depart the Board.
Mr. Rush, age 56, has extensive experience in financial
management and operational development, and is currently Chief
Operating Officer of Miami-based Cosmetic Dermatology, Inc.
Previously, he held positions as CFO of Bijoux Terner, LLC; CFO of
Little Switzerland, Inc; and VP Sales Operations of Rewards
Network, Inc. He is a CPA with an MBA in International Business,
who has also held financial management roles at multi-national
companies Sunglass Hut International, Burger King Corporation and
Knight-Ridder, Inc. He began his career with Big-4 firms Ernst
& Young and Deloitte & Touche.
Adrian Liddell, Chairman of Vycor commented: "We view the
building of a strong and independent board as a critical component
of Vycor's accelerating business development and welcome Lowell
Rush onto the Board. Lowell has tremendous depth in financial and
operating experience and will provide a valuable role to the board
and management as Vycor continues to develop its business and
operations. We also would like to thank Heather for her 8 years of
prior service and contributions and wish her all the best in her
future endeavors."
About Vycor Medical, Inc. With corporate
headquarters in Boca Raton, FL, Vycor Medical, Inc. ("Vycor") is a
publicly traded company (OTCBB: VYCO) dedicated to providing the
medical community with innovative and superior surgical and
therapeutic solutions and has a growing portfolio of FDA-approved
medical solutions that are changing and improving lives every day.
The Company operates two business units: Vycor Medical and
NovaVision, both of which adopt a minimally or non-invasive
approach. Both technologies have exceptional sales growth
potential, address large potential markets, have the requisite
regulatory approvals and are commercialized and generating revenue.
The Company has a strong patent portfolio with 34 granted patents
and a further 21 patents pending.
Vycor Medical's flagship, ViewSite™ Surgical Access Systems
(VBAS) is a suite of clear cylindrical minimally invasive
disposable devices that hold the potential for speedier, safer and
more economical brain surgeries and a quicker patient discharge.
VBAS is designed to optimize neurosurgical site access, reduce
patient risk, accelerate recovery and add tangible value to the
professional medical community. Vycor Medical is ISO 13485:2003
compliant, has FDA 510(K) clearance for VBAS for brain and spine
surgeries and regulatory approvals for brain surgeries in
Australia, Canada, China, Europe, Japan, Korea and Russia. For an
overview of Vycor Medical's VBAS see
http://player.vimeo.com/video/39766887
NovaVision develops and provides science-driven neurostimulation
therapy and other medical technologies that help improve and
partially restore sight in patients with neurological vision
impairments. The company's proprietary Visual Restoration Therapy
(VRT) platform is clinically supported to improve lost vision
resulting from stroke, traumatic brain injury ("TBI"), or other
acquired brain injuries. VRT is the only FDA 510K cleared medical
device in the U.S. aimed at the restoration of vision for
neurologically induced vision loss and can be prescribed by any
ophthalmologist, optometrist, neurologist or physiatrist. VRT also
has CE Marking for the EU. NovaVision also provides Neuro-Eye
Therapy (NeET) in the EU, aimed at increasing visual sensitivity
deep within the field defect. NovaVision also provides a fully
portable and ADA-compliant Head Mounted Perimeter (HMP™) which aids
in the detection and measurement of visual field deficits. For an
overview of NovaVision see
http://player.vimeo.com/video/39765566
For the latest information on the company, including media and
other coverage, and to learn more, please go online at
www.vycormedical.com or www.novavision.com.
Safe Harbor Statement
Information in this document constitute
forward-looking statements or statements which may be deemed or
construed to be forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. The words
"forecast", "anticipate", "estimate", "project", "intend",
"expect", "should", "believe", and similar expressions are intended
to identify forward-looking statements. These forward-looking
statements involve, and are subject to known and unknown risks,
uncertainties and other factors which could cause Vycor Medical's
actual results, performance (financial or operating) or
achievements to differ from the future results, performance
(financial or operating) or achievements expressed or implied by
such forward-looking statements. The risks, uncertainties and other
factors are more fully discussed in Vycor Medical's filings with
the U.S. Securities and Exchange Commission. All forward-looking
statements attributable to Vycor Medical herein are expressly
qualified in their entirety by the above-mentioned cautionary
statement. Vycor Medical disclaims any obligation to update
forward-looking statements contained in this estimate, except as
may be required by law.
Vycor Medical, Inc Investor Contacts: The Del Mar
Consulting Group, Inc. Robert B. Prag President 858-794-9500 Email
Contact or Alex Partners, LLC Scott Wilfong President 425-242-0891
Email Contact
Vycor Medical (QB) (USOTC:VYCO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vycor Medical (QB) (USOTC:VYCO)
Historical Stock Chart
From Jul 2023 to Jul 2024